Key technologies and capabilities for this role
Common questions about this position
Preferred qualifications include an MS in medical technology, clinical laboratory science, chemical, physical or biological science with 0-2 years of pertinent clinical laboratory experience in molecular biology, or a BS with similar experience.
The current available shift is Tues-Sat: 12:00PM-8:30PM, with shift assignment based on technical level, experience, and current business needs.
Highly desirable skills include experience with next-generation sequencing, work in a CLIA/CAP high-complexity laboratory, experience with robotics and automated liquid handling systems, and knowledge of LIMS platforms.
Tempus values a fast-paced environment, interdisciplinary teamwork with minimal direction, self-driven individuals, excellent communication, and a strong desire to build life-saving products in precision medicine.
Strong candidates have impeccable attention to detail, excellent communication skills, thrive in fast-paced settings, and possess highly desirable experience like next-generation sequencing in CLIA/CAP labs.
AI-driven healthcare data analysis platform
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.